DENVER--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced results from a long-term study comparing SYMBICORT ® (budesonide/ formoterol fumarate dihydrate) Inhalation Aerosol 160/4.5 mcg with ...

The dosage for Symbicort may vary based on age and diagnosis, but it’s typically two inhalations twice daily. For children ages 6 to 11, the maximum strength is 80/4.5 mcg. For ages 12 and older, a ...

Symbicort is an inhaler used for long-term control of asthma and COPD, but it is not a rescue inhaler. Before using Symbicort, tell your healthcare provider if you have health conditions like adrenal ...

The studies examined the efficacy of Symbicort pressurized metered dose inhaler (pMDI) 160/4.5mcg vs. formoterol 4.5mcg in reducing COPD exacerbations in adults with moderate to severe COPD. The FDA ...

For patients with COPD, the approved dosage of SYMBICORT is 160/4.5 mcg, 2 inhalations twice daily. The most common adverse events greater than or equal to 3% reported in COPD clinical trials included ...

SYMBICORT 80/4.5 and 160/4.5 were already approved in the US to treat asthma in patients 12 years and older. In September 2017, SYMBICORT160/4.5 was approved for reducing exacerbations in patients ...

The US Food and Drug Administration has approved AstraZeneca's Symbicort inhalation aerosol (80/4.5 mcg) for children aged 6 to 12 years with asthma that is not well controlled with an inhaled ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a US comparative effectiveness study of two maintenance treatment options for patients with a history of chronic obstructive pulmonary disease (COPD) ...

LONDON (MarketWatch) -- Drugmaker AstraZeneca said Monday that the U.S. Food and Drug Administration has approved Symbicort 160/4.5 mcg for the twice daily maintenance treatment of airflow obstruction ...

SYMBICORT (Budesonide 160mcg, formoterol 4.5mcg) inhaler by AstraZeneca The FDA has approved Symbicort 160/4.5 micrograms (budesonide/formoterol fumarate dehydrate ...